GlassScriptPhysician profile
Raymonda Rastegar
NPI 1609888403
$278,457.95
in general payments reported to CMS, 2019-2025
41 companies · $65K in 2025
The $65K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $3,296 · 2021: $4,147 · 2022: $103K · 2023: $61K · 2024: $20K · 2025: $65K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120K · Travel and Lodging: $13K · Food and Beverage: $9,327 · Consulting Fee: $3,295 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120,216.56 |
| Travel and Lodging | $13,170.18 |
| Food and Beverage | $9,327.45 |
| Consulting Fee | $3,294.77 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $236,434.64 | 2019-2025 | Ozempic, Wegovy |
| Amarin Pharma, INC. | $18,666.27 | 2019-2022 | |
| Lexicon Pharmaceuticals, INC. | $3,535.01 | 2023-2024 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,352.83 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,781.97 | 2019-2025 | Wainua, Farxiga, Lokelma |
| Pfizer INC. | $1,651.38 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $1,473.71 | 2019-2024 | |
| Amgen INC. | $1,202.85 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $1,156.49 | 2020-2025 | Nexletol |
| Janssen Pharmaceuticals, INC | $1,143.37 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $985.10 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Actelion Pharmaceuticals US, INC. | $763.94 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Kowa Pharmaceuticals America, INC. | $729.79 | 2019-2024 | Livalo |
| Novartis Pharmaceuticals Corporation | $697.11 | 2019-2025 | |
| Biotronik INC. | $678.81 | 2019-2025 | Biomonitor |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $617.17 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $528.21 | 2019-2024 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx |
| Bayer Healthcare Pharmaceuticals INC. | $459.07 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $425.73 | 2019-2025 | Eliquis, Camzyos |
| Alnylam Pharmaceuticals INC. | $416.46 | 2020-2025 | Amvuttra, Onpattro |
| Abbott Laboratories | $367.09 | 2020-2023 | Mitraclip |
| Medtronic Vascular, INC. | $355.51 | 2019-2020 | |
| Medtronic, INC. | $313.88 | 2022-2023 | Linq II |
| Lundbeck LLC | $251.09 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $235.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $220.40 | 2020-2025 | Trelegy Ellipta |
| Akcea Therapeutics, INC. | $174.93 | 2019-2020 | |
| Bridgebio Pharma, INC. | $153.52 | 2025 | Attruby |
| G Medical Diagnostic Services, INC. | $140.43 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $120.79 | 2019-2021 | |
| Corcept Therapeutics | $79.81 | 2025 | Korlym |
| Vifor Pharma, INC. | $63.11 | 2021 | |
| Medicomp INC | $56.82 | 2025 | Telepatch Cardiac Monitor |
| Currax Pharmaceuticals LLC | $49.67 | 2024-2025 | Contrave |
| Azurity Pharmaceuticals, INC. | $48.58 | 2023 | Edarbi |
| Agepha Pharma Fz LLC | $27.93 | 2024 | Lodoco |
| Heartflow, INC. | $22.63 | 2025 | |
| Ani Pharmaceuticals, INC. | $22.40 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $20.57 | 2021 | |
| Philips North America LLC | $16.86 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $16.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymonda Rastegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.